RE:One more look at the new 90 day optimized data
Eoganacht wrote: I changed the percentages to patient counts for the recent 90 day numbers for the:
23 patients enrolled and treated in Study II who received an optimized primary study treatment
CR = 12
PR = 4
Pending = 3
NR = 4
Potential CR = 82%
In the last newsletter there were 18 post-Aug 20 2020 optimized patients
CR = 8
PR = 2
Pending = 7
NR = 1
Potential CR = 94.4%
In the period between the two news releases 7 patients reached 90 days and 5 more patients were treated for a total of 12 patients. Of these 12 patients there were:
CR = 4
PR = 2
Pending = 3
NR = 3
Potential CR = 75%
Out of these 12 patients 3 patients (25%) were NR. The results of just these 3 patients accounts for the drop in 90 day potential CR. We will probably never know what happened with these 3 probably very sick and elderly patients but given where we are in the trial it will likely have little overall effect. If you flip a coin 12 times you won't likely get 6 heads and 6 tails. You might get 4 tails and 8 heads. But if you fip a coin 100 times it will be much closer to 50% heads and 50% tails. If those 3 patients had been CR or PR we would have a 90 day potential CR of 96% and the sp would have reached new heights IMHO. But this isn't the first time Theralase's sp has taken an unexpected and unwarranted hit.
Thanks for beating me to the punch Eoganacht ; )...The absolute numbers certainly paint a more clear & rosy picture of where the data is truly heading.
For those few who convert from CR/PR to NR, I'm still hoping such patients in the future could benefit from an additional treatment(s). If the ACT was proven to work once, it's certainly plausible it can work again. As goosey noted in an earlier post, select patients may also benefit from a different method of drug delivery that could help maximize drug uptake (i.e. body position changes &/or eventually IV Rutherrin). Such modifications could be especially beneficial for those with cancer sites that are less treatment-friendly or for those with comorbities that can cause significant bladder wall thickening/changes. JMO.
In terms of a larger data sample, it would also be interesting to know if NRs are occurring in all trial sites, or are they limited to a very few/one? Imo, a significant number of NRs are less likely a result of the drug/tech & more from external factors that can't easily be controlled for. JMO & good luck...